ESSA Pharma Inc
NASDAQ:EPIX
Intrinsic Value
ESSA Pharma, Inc. is a clinical stage pharmaceutical company. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of EPIX.
ESSA Pharma Inc's market capitalization is 270.3m USD.
EPIX stock price is 6.12 USD.
EPIX.
EPIX. Open DCF Valuation
EPIX. Open Relative Valuation
EPIX has upside potential of 217% compared to the average analyst price target.
Open Wall St Estimates
EPIX has negative Free Cash Flow for the last twelve months.
EPIX's ROE (Return on Equity) has increased in the last 3 years from -24% to -17%, and is approaching profitability.
EPIX has negative Operating Income for the last twelve months.
EPIX has negative Net Income for the last twelve months.
EPIX's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -28 152% to -91 921%, and is approaching profitability.
EPIX's ROE (Return on Equity) for the past 12 months is negative and is equal to -17%.
EPIX's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -91 921%.
EPIX has negative three-year average ROE (Return on Equity): -23%. The company is not efficient at transforming stockholders' equity into net income.
EPIX has negative three-year average ROIC (Return on Invested Capital): -15 309%. The company is not efficient at using invested capital to generate operating income.
EPIX's short-term assets (144m USD) exceed its short-term liabilties (4m USD).
EPIX's long-term assets (144m USD) exceed its long-term liabilties (4m USD).
EPIX's D/E (Debt to Equity) is very low and is equal to 0.
EPIX's Altman Z-Score is very high and is equal to 43.41.
Fundamental Analysis
ESSA Pharma Inc
Balance Sheet Decomposition
ESSA Pharma Inc
| Current Assets | 143.9m |
| Cash & Short-Term Investments | 142.1m |
| Receivables | 180.6k |
| Other Current Assets | 1.6m |
| Non-Current Assets | 620.4k |
| PP&E | 363.2k |
| Other Non-Current Assets | 257.2k |
| Current Liabilities | 3.5m |
| Accounts Payable | 2.6m |
| Accrued Liabilities | 930.7k |
| Non-Current Liabilities | 275.4k |
| Other Non-Current Liabilities | 275.4k |
Earnings Waterfall
ESSA Pharma Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-31.9m
USD
|
|
Operating Income
|
-31.9m
USD
|
|
Other Expenses
|
6.1m
USD
|
|
Net Income
|
-25.8m
USD
|
Free Cash Flow Analysis
ESSA Pharma Inc
EPIX Profitability Score
Profitability Due Diligence
ESSA Pharma Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
Score
ESSA Pharma Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
EPIX Solvency Score
Solvency Due Diligence
ESSA Pharma Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
ESSA Pharma Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
EPIX Price Targets Summary
ESSA Pharma Inc
According to Wall Street analysts, the average 1-year price target for
EPIX
is 19.38 USD
with a low forecast of 15.15 USD and a high forecast of 30.45 USD.
Ownership
EPIX Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
EPIX Price
ESSA Pharma Inc
| Average Annual Return | 47.53% |
| Standard Deviation of Annual Returns | 100.01% |
| Max Drawdown | -96% |
| Market Capitalization | 270.3m USD |
| Shares Outstanding | 44 240 000 |
| Percentage of Shares Shorted | 3.02% |
Company Profile
ESSA Pharma Inc
Country
Industry
Market Cap
Dividend Yield
Description
ESSA Pharma, Inc. is a clinical stage pharmaceutical company. The company is headquartered in Vancouver, British Columbia and currently employs 30 full-time employees. The firm is focused on developing therapies for the treatment of prostate cancer. The Company’s lead candidate, EPI-7386 is an oral, small molecule that inhibits the androgen receptor (AR) through a novel mechanism of action (N-terminal domain inhibition). The firm is evaluating EPI-7386 as a monotherapy for the treatment of adult male patients with metastatic castration-resistant prostate cancer (mCRPC) resistant to standard-of-care treatments.
You don't have any saved screeners yet
